Detail akcie Helius Med Rg-A online

Business Summary: Helius Medical Technologies, Inc. is a neurotechnology company. The Company is engaged in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy utilizes the PoNS device in conjunction with supervised therapeutic exercise. The PoNS Therapy consists of condition-specific exercises for movement control, including balance and gait training and breathing and awareness training, which are tailored to focus on the individual patient’s functional deficits.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Helius Medical Technologies Inc revenues decreased 64% to $49K. Net loss increased 53% to $3.8M. Revenues reflect United States segment decrease of 76% to $19K, Canada segment decrease of 58% to $19K. Higher net loss reflects Electromedical Equipment segment loss increase of 17% to $4M. Basic Earnings per Share excluding Extraordinary Items increased from -$46.17 to -$7.62.